<DOC>
	<DOCNO>NCT01624974</DOCNO>
	<brief_summary>The purpose study evaluate effect MK-1029 lung function treatment adult persistent asthma uncontrolled use montelukast ( ML ) . Participants use randomize study drug ( either MK-1029 placebo ) two separate 4-week treatment period . All participant also use ML treatment period .</brief_summary>
	<brief_title>Study Evaluate Effectiveness Safety MK-1029 Treatment Persistent Asthma That Not Controlled With Montelukast ( ML ) Adults ( MK-1029-011 AM2 )</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>pregnant breastfeeding plan become pregnant duration study ; symptom persistent asthma least one year ; current use asthma treatment : 1 ) `` asneeded '' inhale SABAs ( albuterol/salbutamol ) asthma controller least 4 week prior Screening Visit OR 2 ) stable dose ICS , combination ICS/LABA and/or oral asthma controller ( ) least 4 week prior Screening Visit able tolerate discontinue controller receive ML ; history smoking OR smoking least 1 year , smoke history 10 packyears ; able maintain constant day/night , awake/sleep cycle ; agree change habitual consumption beverage foods contain caffeine throughout study ; Body Mass Index ( BMI ) 15 kg/m^2 40 kg/m^2 . history myocardial infarction , congestive heart failure , uncontrolled cardiac arrhythmia within 3 month prior Screening Visit ; hospitalize hospitalization within 4 week prior Screening Visit ; intention move anticipation miss study visit ; major surgical procedure ( ) within 4 week prior Screening Visit ; participation clinical trial involve investigational drug within 4 week prior Screening Visit ; current regular use recent past abuse ( within past 5 year ) alcohol ( &gt; 14 drinks/week ) illicit drug ; donation unit blood within 2 week prior Screening Visit intention donate unit blood study ; evidence another active pulmonary disorder bronchiectasis COPD ; treatment emergency room asthma within 4 week prior Screening Visit hospitalization asthma within 2 month prior Screening Visit ; respiratory tract infection require treatment antibiotic within 2 month prior Screening Visit ; evidence active sinus disease within 1 week prior Screening Visit ; history psychiatric disorder , stable depression , within 3 month prior Screening Visit ; history human immunodeficiency virus ( HIV ) ; hypersensitivity intolerance inhale betaagonists and/or leukotriene inhibitor ingredient , include lactose galactose ; unstable disease ophthalmologic , neurological , hepatic , renal , connective tissue , genitourinary , gastrointestinal , cardiovascular hematologic system ; cancer ( except successfully treat basal squamous cell carcinoma skin ) history cancer within 5 year prior Screening Visit ; uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>